2024
The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia
Liu M, Ren Y, Zhou Z, Yang J, Shi X, Cai Y, Arreola A, Luo W, Fung K, Xu C, Nipp R, Bronze M, Zheng L, Li Y, Houchen C, Zhang Y, Li M. The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia. Cancer Cell 2024, 42: 885-903.e4. PMID: 38608702, PMCID: PMC11162958, DOI: 10.1016/j.ccell.2024.03.009.Peer-Reviewed Original ResearchConceptsPancreatic cancer cachexiaTumor cellsCancer cachexiaTherapeutic targetLimited treatment optionsPancreatic cancer cellsImmune microenvironmentCCL2/CCR2 axisPotential therapeutic targetTreatment optionsMuscle wastingReprogram macrophagesTumorMuscle atrophyCachexiaCancer cellsMacrophagesNon-autonomous activationMuscle remodelingCancerMuscle degradationSecretionCellsMuscleTWEAK
2023
Combining ASBT inhibitor and FGF15 treatments enhances therapeutic efficacy against cholangiopathy in female but not male Cyp2c70 KO mice
Hasan M, Chen J, Matye D, Wang H, Luo W, Gu L, Clayton Y, Du Y, Li T. Combining ASBT inhibitor and FGF15 treatments enhances therapeutic efficacy against cholangiopathy in female but not male Cyp2c70 KO mice. Journal Of Lipid Research 2023, 64: 100340. PMID: 36737039, PMCID: PMC9986646, DOI: 10.1016/j.jlr.2023.100340.Peer-Reviewed Original ResearchConceptsBile acid poolKO miceTherapeutic efficacyHepatobiliary injuryBile acid pool sizeBile acid exposureGut barrier integrityGut barrier functionBile acid metabolismAcid poolBile acid synthesisAcid pool sizeBile acid uptakePortal inflammationPortal fibrosisGut exposureDuctular reactionGSK2330672Therapeutic reductionUrsodeoxycholic acidMuricholic acidAcid exposureASBT inhibitorSevere cholangiopathyBarrier integrity
2022
Acetyl-Coenzyme A Synthetase 2 Potentiates Macropinocytosis and Muscle Wasting Through Metabolic Reprogramming in Pancreatic Cancer
Zhou Z, Ren Y, Yang J, Liu M, Shi X, Luo W, Fung K, Xu C, Bronze M, Zhang Y, Houchen C, Li M. Acetyl-Coenzyme A Synthetase 2 Potentiates Macropinocytosis and Muscle Wasting Through Metabolic Reprogramming in Pancreatic Cancer. Gastroenterology 2022, 163: 1281-1293.e1. PMID: 35777482, PMCID: PMC9613512, DOI: 10.1053/j.gastro.2022.06.058.Peer-Reviewed Original ResearchConceptsMetabolic reprogrammingDynamin 2Transcriptional activationShort palindromic repeat-associated protein 9 (CRISPR/Cas9) systemSingle-cell RNA sequencing dataRNA sequencing dataProtein 9 (Cas9) systemGlycogen synthase kinasePancreatic cancerEpigenetic reprogrammingFamily member 2Chromatin immunoprecipitationMuscle wastingDownstream targetsSequencing dataSyndecan-1ReprogrammingSynthase kinaseWorse prognosisMacropinocytosisZIP4ACSS2Mouse modelProtein 4Uptake assaysCircular RNA ANAPC7 Inhibits Tumor Growth and Muscle Wasting via PHLPP2–AKT–TGF-β Signaling Axis in Pancreatic Cancer
Shi X, Yang J, Liu M, Zhang Y, Zhou Z, Luo W, Fung K, Xu C, Bronze M, Houchen C, Li M. Circular RNA ANAPC7 Inhibits Tumor Growth and Muscle Wasting via PHLPP2–AKT–TGF-β Signaling Axis in Pancreatic Cancer. Gastroenterology 2022, 162: 2004-2017.e2. PMID: 35176309, PMCID: PMC10428768, DOI: 10.1053/j.gastro.2022.02.017.Peer-Reviewed Original ResearchConceptsZinc-dependent transcription factorsFunction of circRNAsMiR-373Dephosphorylation of AktDephosphorylation of CREBNovel tumor suppressorCyclin D1Feed-forward loopMouse skeletal muscleHuman pancreatic cancer cellsRNA interactionsTumor growthTranscription factorsCircular RNAsPancreatic cancer progressionMuscle wastingAkt dephosphorylationRNA immunoprecipitationCancer cell proliferationDownstream targetsPancreatic cancer cellsTumor suppressorSilico analysisPancreatic cancerSignaling AxisExpression and Potential Prognostic Value of SOX9, MCL-1 and SPOCK1 in Gastric Adenocarcinoma
Luo W, Nagaria T, Sun H, Ma J, Lombardo J, Bassett R, Cao A, Tan D. Expression and Potential Prognostic Value of SOX9, MCL-1 and SPOCK1 in Gastric Adenocarcinoma. Pathology & Oncology Research 2022, 28: 1610293. PMID: 35221802, PMCID: PMC8863590, DOI: 10.3389/pore.2022.1610293.Peer-Reviewed Original ResearchConceptsGastric cancerPrognostic valueGastric adenocarcinomaMcl-1Pathologic TNM stageDifferent treatment modalitiesCancer-related deathPotential prognostic valueFurther subgroup analysisNegative prognostic markerTumor heterogeneityDifferent molecular alterationsSOX9 expressionSPOCK1 expressionPrognostic roleCommon malignancyPoor prognosisTNM stageTreatment modalitiesSubgroup analysisPrognostic markerUnivariate analysisDisease prognosisDivergent differentiationMolecular alterations
2021
NUTM1-Rearranged Neoplasms—A Heterogeneous Group of Primitive Tumors with Expanding Spectrum of Histology and Molecular Alterations—An Updated Review
Luo W, Stevens T, Stafford P, Miettinen M, Gatalica Z, Vranic S. NUTM1-Rearranged Neoplasms—A Heterogeneous Group of Primitive Tumors with Expanding Spectrum of Histology and Molecular Alterations—An Updated Review. Current Oncology 2021, 28: 4485-4503. PMID: 34898574, PMCID: PMC8628659, DOI: 10.3390/curroncol28060381.Peer-Reviewed Original ResearchConceptsGenome-wide histone modificationsPost-meiotic spermatidsExpression of oncogenesTumor suppressor geneTranscription regulationHistone modificationsBromodomain proteinsNuclear proteinsRNA sequencingFusion proteinProtein productsSuppressor geneFusion partnerGenesSitu hybridizationDifferent clinical coursesProteinSkin adnexal tumorsPrimitive morphologyOncogenic driversInhibitor therapyClinical courseMolecular alterationsPrimitive tumorHematologic malignanciesAn integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancer
Zhou Z, Zhang J, Xu C, Yang J, Zhang Y, Liu M, Shi X, Li X, Zhan H, Chen W, McNally L, Fung K, Luo W, Houchen C, He Y, Zhang C, Li M. An integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancer. EBioMedicine 2021, 65: 103271. PMID: 33714027, PMCID: PMC7966986, DOI: 10.1016/j.ebiom.2021.103271.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsPancreatic ductal adenocarcinomaImmune evasionCheckpoint inhibitorsOverall survivalImmune infiltrationPancreatic cancerTumor aggressivenessM6A regulatorsSomatic copy number alterationsT cell exhaustionDismal overall survivalMutation profilesN6-methyladenosine regulatorsHigh response ratePancreatic cancer prognosisClassical pancreatic ductal adenocarcinomaCancer CenterColorectal cancerTumor recurrenceDuctal adenocarcinomaM6AscoreBreast cancerTreatment responseCell exhaustionZinc-Dependent Regulation of ZEB1 and YAP1 Coactivation Promotes Epithelial-Mesenchymal Transition Plasticity and Metastasis in Pancreatic Cancer
Liu M, Zhang Y, Yang J, Zhan H, Zhou Z, Jiang Y, Shi X, Fan X, Zhang J, Luo W, Fung K, Xu C, Bronze M, Houchen C, Li M. Zinc-Dependent Regulation of ZEB1 and YAP1 Coactivation Promotes Epithelial-Mesenchymal Transition Plasticity and Metastasis in Pancreatic Cancer. Gastroenterology 2021, 160: 1771-1783.e1. PMID: 33421513, PMCID: PMC8035249, DOI: 10.1053/j.gastro.2020.12.077.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAnimalsCation Transport ProteinsCell Line, TumorCell MovementCell PlasticityEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansIntegrin alpha3MiceMicroRNAsNeoplasm InvasivenessNeoplasm MetastasisPancreatic NeoplasmsSignal TransductionSpheroids, CellularTranscription FactorsYAP-Signaling ProteinsZincZinc Finger E-box-Binding Homeobox 1ConceptsEMT plasticityHuman pancreatic cancer cellsPancreatic cancer cellsZinc-dependent regulationHippo pathway effector YAP1Cancer cellsMiR-373Zinc transporter ZIP4Potent transcriptional coactivatorMesenchymal-epithelial transition (MET) statesAssociate domainTranscriptional regulationChromatin immunoprecipitationEffector YAP1Transcriptional coactivatorYAP1/Downstream targetsPancreatic cancer metastasisMouse cellsMolecular eventsZIP4YAP1Cell adhesionLuciferase reporterSpontaneous mouse model
2020
Genomic and single cell sequencing facilitate the dissection of heterogeneity of pancreatic tumors
Edil B, Luo W, Li M. Genomic and single cell sequencing facilitate the dissection of heterogeneity of pancreatic tumors. BMC Medicine 2020, 18: 177. PMID: 32635908, PMCID: PMC7341579, DOI: 10.1186/s12916-020-01637-3.Peer-Reviewed Original ResearchGastrointestinal Injury Related to Antiangiogenesis Cancer Therapy
Tang T, Abu-Sbeih H, Ma W, Lu Y, Luo W, Foo W, Richards D, Halperin D, Ge P, Wang Y. Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy. Clinical Colorectal Cancer 2020, 19: e117-e123. PMID: 32284253, DOI: 10.1016/j.clcc.2020.03.002.Peer-Reviewed Original ResearchConceptsAbnormal endoscopic findingsAntiangiogenesis cancer therapyIntensive care unitAntiangiogenesis therapyACD symptomsAntimotility agentsEndoscopic findingsColonic perforationCare unitTertiary care cancer centerActive histologic inflammationRare adverse eventsCancer therapyEnterocolitis symptomsHistologic inflammationNonulcerative inflammationUnderlying malignancyGastrointestinal injuryGastrointestinal toxicityMucosal ulcerationUnderwent endoscopyAdverse eventsMedian durationMost patientsEndoscopic evaluationNeutropenic Enterocolitis: Clinical Features and Outcomes.
Abu-Sbeih H, Ali F, Chen E, Mallepally N, Luo W, Lu Y, Foo W, Qiao W, Okhuysen P, Adachi J, Hachem R, Altan M, Jenq R, Wang Y. Neutropenic Enterocolitis: Clinical Features and Outcomes. Diseases Of The Colon & Rectum 2020, 63: 381-388. PMID: 31842164, DOI: 10.1097/dcr.0000000000001548.Peer-Reviewed Original ResearchConceptsMD Anderson Cancer CenterNeutropenic enterocolitisGranulocyte colony-stimulating factorAnderson Cancer CenterCancer CenterColony-stimulating factorMucosal injuryClinical featuresSurvival rateTexas MD Anderson Cancer CenterConcomitant systemic infectionImmunosuppressive therapy useDuration of neutropeniaRetrospective cohort studyAbsolute neutrophil countCox regression analysisComprehensive cancer centerLower survival rateAbdominal symptomsEnterocolitis diagnosisEnterocolitis symptomsNeutropenia onsetPneumatosis intestinalisCohort studyColonic perforation
2019
Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy
Abu-Sbeih H, Tang T, Ali F, Luo W, Neelapu S, Westin J, Okhuysen P, Foo W, Curry J, Richards D, Ge P, Wang Y. Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy. American Journal Of Clinical Oncology 2019, 42: 789-796. PMID: 31478934, DOI: 10.1097/coc.0000000000000596.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge DistributionAntineoplastic Combined Chemotherapy ProtocolsAsparaginaseBiopsy, NeedleCohort StudiesCytarabineDaunorubicinFemaleGastric MucosaGastritisGastrointestinal DiseasesHematologic NeoplasmsHumansImmunohistochemistryImmunotherapy, AdoptiveIncidenceMaleMiddle AgedPrognosisReceptors, Chimeric AntigenRetrospective StudiesRisk AssessmentSeverity of Illness IndexSex DistributionThioguanineConceptsChimeric antigen receptor T-cell therapyCytokine release syndromeGastrointestinal adverse eventsGI AEsT-cell therapyRefractory colitisEncephalopathy syndromeRelease syndromeAdverse eventsHematologic malignanciesDiffuse large B-cell lymphomaLarge B-cell lymphomaGastrointestinal tract inflammationGrade 1 diarrheaOnly symptomatic treatmentStandard of careCertain hematologic malignanciesB-cell lymphomaCART infusionAbdominal distensionAbdominal painBloody stoolGastrointestinal symptomsMedian durationExperienced diarrheaUpper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors
Tang T, Abu-Sbeih H, Luo W, Lum P, Qiao W, Bresalier R, Richards D, Wang Y. Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scandinavian Journal Of Gastroenterology 2019, 54: 538-545. PMID: 31079556, DOI: 10.1080/00365521.2019.1594356.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsUpper GI symptomsRisk factorsGI symptomsCheckpoint inhibitorsGI inflammationAnti-PD-1/L1Non-steroidal anti-inflammatory drugsUpper GI injuryUpper GI toxicityGastrointestinal adverse eventsUpper gastrointestinal symptomsProton pump inhibitorsLower GI tractAnti-inflammatory drugsRate of ulcerationGI injuryICI initiationDuodenal involvementEndoscopic evidenceGastrointestinal symptomsGI toxicityImmunosuppressive therapyAdverse eventsGastric involvementAcute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab
Zhang H, Luo W, Wang Y. Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab. Journal For ImmunoTherapy Of Cancer 2019, 7: 47. PMID: 30777137, PMCID: PMC6380028, DOI: 10.1186/s40425-019-0532-1.Peer-Reviewed Original ResearchConceptsImmune-related adverse reactionsGrade 3 colitisGastrointestinal reactionsLiver injuryClinical historyImmune checkpoint inhibitor-related colitisBackgroundImmune checkpoint inhibitorsElevated liver enzymesPD-1 inhibitorsTNF-α agentsAcute liver injuryInflammatory bowel diseaseOne-time infusionInfliximab therapyAcute hepatitisCheckpoint inhibitorsRescue therapyAdvanced malignanciesBiologic agentsBowel diseaseLiver profileCase presentationWePatient populationCTLA-4Final diagnosisGastroesophageal junction Paneth cell carcinoma with extensive cystic and secretory features – case report and literature review
Luo W, Hofstetter W, Tan D. Gastroesophageal junction Paneth cell carcinoma with extensive cystic and secretory features – case report and literature review. Diagnostic Pathology 2019, 14: 1. PMID: 30621725, PMCID: PMC6323739, DOI: 10.1186/s13000-018-0775-z.Peer-Reviewed Original ResearchConceptsNeoplastic Paneth cellsGastroesophageal junctionCell carcinomaPaneth cellsImmunohistochemical stainsProton pump inhibitor therapySubsequent endoscopic mucosal resectionHER2/neu statusBeta-catenin pathwayUpper gastrointestinal bleedingDiagnosis of adenocarcinomaEndoscopic mucosal resectionHER2/neuPeculiar histologic featuresDistinct staining patternsGastrointestinal bleedingCase presentationAInhibitor therapyClinical courseMucosal resectionHistologic featuresBarrett's esophagusEmergency roomTypical adenocarcinomaSecretory changes
2018
Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study
Abu-Sbeih H, Ali F, Alsaadi D, Jennings J, Luo W, Gong Z, Richards D, Charabaty A, Wang Y. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study. Journal For ImmunoTherapy Of Cancer 2018, 6: 142. PMID: 30518410, PMCID: PMC6280383, DOI: 10.1186/s40425-018-0461-4.Peer-Reviewed Original ResearchConceptsMean durationImmune checkpoint inhibitor-induced colitisCheckpoint inhibitor-induced colitisImmune checkpoint inhibitor treatmentAbnormal endoscopic findingsActive histologic inflammationCheckpoint inhibitor treatmentClinical success rateRetrospective case seriesGood safety profileFeatures of chronicityMulti-center studyEndoscopic remissionHistologic inflammationHistologic remissionICI therapyNonulcerative inflammationSteroid therapyVedolizumab infusionsVedolizumab therapyClinical remissionMicroscopic colitisMucosal ulcerationSystemic immunosuppressionAdvanced malignanciesImportance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis
Abu-Sbeih H, Ali F, Luo W, Qiao W, Raju G, Wang Y. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. Journal For ImmunoTherapy Of Cancer 2018, 6: 95. PMID: 30253811, PMCID: PMC6156850, DOI: 10.1186/s40425-018-0411-1.Peer-Reviewed Original ResearchConceptsEndoscopic featuresClinical outcomesHistologic featuresGrade 3Immune checkpoint inhibitor-induced colitisCheckpoint inhibitor-induced colitisLogistic regressionActive histologic inflammationActive histological inflammationBackgroundImmune checkpoint inhibitorsExtensive colonic involvementMore frequent hospitalizationsMore recurrent symptomsHigh-risk featuresMultivariate logistic regressionSuch adverse eventsTime of onsetHistologic inflammationICPI treatmentCheckpoint inhibitorsColonic involvementEndoscopic inflammationHistological inflammationMucosal ulcerationRecurrent symptoms
2017
HuR promotes the molecular signature and phenotype of activated microglia: Implications for amyotrophic lateral sclerosis and other neurodegenerative diseases
Matsye P, Zheng L, Si Y, Kim S, Luo W, Crossman D, Bratcher P, King P. HuR promotes the molecular signature and phenotype of activated microglia: Implications for amyotrophic lateral sclerosis and other neurodegenerative diseases. Glia 2017, 65: 945-963. PMID: 28300326, PMCID: PMC7944581, DOI: 10.1002/glia.23137.Peer-Reviewed Original ResearchConceptsAmyotrophic lateral sclerosisNeurodegenerative diseasesIL-1βLateral sclerosisALS spinal cordMutant SOD1 micePossible therapeutic targetTranscription factor NF-κBLipopolysaccharide-induced IL-1βFactor NF-κBMolecular signaturesRole of HuRLuciferase reporter studiesActivated microgliaProinflammatory factorsSOD1 miceIL-6Inflammatory pathwaysMicroglial migrationImmune cellsSpinal cordChronic activationMicrogliaNF-κBTherapeutic target
2014
Mammary analog secretory carcinoma of salivary gland with high-grade histology arising in hard palate, report of a case and review of literature.
Luo W, Lindley S, Lindley P, Krempl G, Seethala R, Fung K. Mammary analog secretory carcinoma of salivary gland with high-grade histology arising in hard palate, report of a case and review of literature. International Journal Of Clinical And Experimental Pathology 2014, 7: 9008-22. PMID: 25674280, PMCID: PMC4313953.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkers, TumorBiopsyBreast NeoplasmsCarcinomaCranial IrradiationFemaleHumansImmunohistochemistryLymphatic MetastasisMagnetic Resonance ImagingNeoplasm GradingOncogene Proteins, FusionPalatal NeoplasmsPalate, HardRadiotherapy, AdjuvantRecombination, GeneticSalivary Gland NeoplasmsTomography, X-Ray ComputedTreatment OutcomeConceptsHigh-grade histologyMinor salivary glandsETV6-NTRK3 translocationSalivary gland tumorsParotid glandSalivary glandsGrade histologySecretory carcinomaHard palateOriginal tumorGland tumorsCervical lymph node metastasisMammary analogue secretory carcinomaPrimary salivary gland tumorsLow histologic gradeLymph node metastasisLow-grade malignancyAcinic cell carcinomaYears of ageHigh-grade transformationYear old adultsReview of literatureOverall prognosisBenign courseNode metastasisHu Antigen R (HuR) Is a Positive Regulator of the RNA-binding Proteins TDP-43 and FUS/TLS Implications for Amyotrophic Lateral Sclerosis*
Lu L, Zheng L, Si Y, Luo W, Dujardin G, Kwan T, Potochick N, Thompson S, Schneider D, King P. Hu Antigen R (HuR) Is a Positive Regulator of the RNA-binding Proteins TDP-43 and FUS/TLS Implications for Amyotrophic Lateral Sclerosis*. Journal Of Biological Chemistry 2014, 289: 31792-31804. PMID: 25239623, PMCID: PMC4231657, DOI: 10.1074/jbc.m114.573246.Peer-Reviewed Original ResearchMeSH Keywords3' Untranslated RegionsAmyotrophic Lateral SclerosisAnimalsAstrocytesCell LineCell Line, TumorCell SurvivalCulture Media, ConditionedCystic Fibrosis Transmembrane Conductance RegulatorDNA-Binding ProteinsELAV ProteinsELAV-Like Protein 1Gene Expression RegulationHumansHypoxiaMiceMotor NeuronsPhenotypeRNARNA-Binding Protein FUSConceptsAmyotrophic lateral sclerosis